The cardiovascular benefits of statinscombined with PCSK9 monoclonal antibodies have been demonstrated in studies suchas Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) and Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY OUTCOMES) [31, 32]. Here, PCSK9 is linked to acute coronary syndrome.